MA41449A - Polythérapies pour le traitement de cancers - Google Patents

Polythérapies pour le traitement de cancers

Info

Publication number
MA41449A
MA41449A MA041449A MA41449A MA41449A MA 41449 A MA41449 A MA 41449A MA 041449 A MA041449 A MA 041449A MA 41449 A MA41449 A MA 41449A MA 41449 A MA41449 A MA 41449A
Authority
MA
Morocco
Prior art keywords
polytherapies
cancers
treatment
Prior art date
Application number
MA041449A
Other languages
English (en)
Inventor
Paolo Julie A Di
Randall Mark Jones
Daniel B Tumas
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55398445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41449(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA41449A publication Critical patent/MA41449A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA041449A 2015-02-03 2016-01-28 Polythérapies pour le traitement de cancers MA41449A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562111604P 2015-02-03 2015-02-03

Publications (1)

Publication Number Publication Date
MA41449A true MA41449A (fr) 2017-12-12

Family

ID=55398445

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041449A MA41449A (fr) 2015-02-03 2016-01-28 Polythérapies pour le traitement de cancers

Country Status (25)

Country Link
US (2) US20180117052A1 (fr)
EP (1) EP3253385A1 (fr)
JP (1) JP2018503653A (fr)
KR (1) KR20170104616A (fr)
CN (1) CN107205992A (fr)
AU (1) AU2016215643A1 (fr)
BR (1) BR112017016019A2 (fr)
CA (1) CA2974828A1 (fr)
CL (1) CL2017001943A1 (fr)
CO (1) CO2017007662A2 (fr)
CR (1) CR20170352A (fr)
CU (1) CU20170099A7 (fr)
EA (1) EA201791516A1 (fr)
EC (1) ECSP17048849A (fr)
GT (1) GT201700167A (fr)
IL (1) IL253573A0 (fr)
MA (1) MA41449A (fr)
MD (1) MD20170073A2 (fr)
MX (1) MX2017009724A (fr)
PE (1) PE20171241A1 (fr)
PH (1) PH12017550063A1 (fr)
SG (1) SG11201706107SA (fr)
SV (1) SV2017005489A (fr)
TW (1) TW201639573A (fr)
WO (1) WO2016126552A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120121A1 (es) 2008-12-08 2012-02-20 Gilead Connecticut Inc Derivados de imidazopirazina como inhibidores de syk
JP5938352B2 (ja) 2010-03-11 2016-06-22 ギリアード コネチカット， インコーポレイテッド イミダゾピリジンｓｙｋ阻害剤
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
EA031601B1 (ru) 2013-07-31 2019-01-31 Джилид Сайэнс, Инк. Ингибиторы syk
AU2014360537B2 (en) 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
CN106687139A (zh) 2014-07-14 2017-05-17 吉利德科学公司 用于治疗癌症的组合
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US10759798B2 (en) * 2016-09-14 2020-09-01 Hangzhou Solipharma Co., Ltd. ABT-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof
EP3512519A1 (fr) 2016-09-14 2019-07-24 Gilead Sciences, Inc. Inhibiteurs de syk
EP4772537A2 (fr) * 2017-04-28 2026-07-08 Actinium Pharmaceuticals, Inc. Procédé de traitement du cancer à l'aide d'un inhibiteur de bcl-2 en association avec une radioimmunothérapie à émission alpha
KR20220070056A (ko) 2017-08-25 2022-05-27 길리애드 사이언시즈, 인코포레이티드 Syk 억제제의 다형체
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
AU2020225455A1 (en) 2019-02-22 2021-09-09 Kronos Bio, Inc. Solid forms of condensed pyrazines as Syk inhibitors
SG11202113356XA (en) 2019-06-12 2021-12-30 Juno Therapeutics Inc Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
CN118542872A (zh) 2019-12-04 2024-08-27 苏州亚盛药业有限公司 药物组合及其用途
WO2022133030A1 (fr) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Polythérapie de thérapie cellulaire et d'inhibiteur de bcl2
JP7898763B2 (ja) * 2021-04-05 2026-08-03 ピノットバイオ インコーポレイテッド ４’－チオ－５－アザ－２’－デオキシシチジンおよびベネトクラクスの併用療法
KR20240144146A (ko) * 2022-02-02 2024-10-02 오노 야꾸힝 고교 가부시키가이샤 Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
GB0326780D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
CA2693310C (fr) 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Inhibiteurs de lox et loxl2, anticorps et utilisations associees
WO2010019702A2 (fr) 2008-08-12 2010-02-18 Oncomed Pharmaceuticals, Inc. Agents de liaison à ddr1 et leurs méthodes d'utilisation
EA020461B1 (ru) * 2008-12-08 2014-11-28 Джилид Коннектикут, Инк. ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
KR20120085781A (ko) 2009-09-20 2012-08-01 아보트 러보러터리즈 Ｂｃｌ-２ 단백질 관련 질환을 치료하는데 사용하기 위한 ａｂｔ-２６３ 결정 형태 및 용매화물
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
WO2011133668A2 (fr) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Méthodes et compositions utilisées pour le traitement du cancer
WO2012027721A2 (fr) 2010-08-27 2012-03-01 Gilead Biologics, Inc Anticorps contre la métalloprotéinase de matrice 9
WO2012071336A1 (fr) 2010-11-23 2012-05-31 Abbott Laboratories Sels et formes cristallines d'un agent inducteur d'apoptose
JP6101205B2 (ja) 2011-08-23 2017-03-22 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
EP2763994A4 (fr) 2011-10-04 2015-08-26 Gilead Calistoga Llc Nouveaux inhibiteurs de quinoxaline de la voie pi3k
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (fr) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions et procédés de traitement d'une maladie avec (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phényl-3,4-dihydroquinazoline-2-yl)éthyl)amino)pyrimidine-5-carbonitrile
AU2013302617A1 (en) * 2012-08-14 2015-02-05 Gilead Calistoga Llc Combination therapies for treating cancer
EP3919079A1 (fr) * 2012-09-07 2021-12-08 Genentech, Inc. Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20
AR092662A1 (es) 2012-09-24 2015-04-29 Gilead Sciences Inc Anticuerpos anti-ddr1
US9029384B2 (en) 2012-12-21 2015-05-12 Gilead Calistoga, LLC. Phosphatidylinositol 3-kinase inhibitors
TW201441216A (zh) 2012-12-21 2014-11-01 Gilead Calistoga Llc 肌醇磷酯３－激酶的抑制劑
ES2667173T3 (es) 2013-06-14 2018-05-09 Gilead Calistoga Llc Inhibidores de fosfatidilinositol 3-quinasa
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
PL3027171T3 (pl) * 2013-07-30 2020-08-24 Gilead Connecticut, Inc. Formulacja inhibitorów syk

Also Published As

Publication number Publication date
US20160220573A1 (en) 2016-08-04
SG11201706107SA (en) 2017-08-30
CU20170099A7 (es) 2018-03-13
BR112017016019A2 (pt) 2018-03-20
IL253573A0 (en) 2017-09-28
CA2974828A1 (fr) 2016-08-11
MD20170073A2 (ro) 2018-02-28
EP3253385A1 (fr) 2017-12-13
CN107205992A (zh) 2017-09-26
KR20170104616A (ko) 2017-09-15
JP2018503653A (ja) 2018-02-08
SV2017005489A (es) 2017-10-17
TW201639573A (zh) 2016-11-16
MX2017009724A (es) 2017-11-17
GT201700167A (es) 2017-11-02
US20180117052A1 (en) 2018-05-03
PH12017550063A1 (en) 2018-02-05
ECSP17048849A (es) 2017-10-31
CL2017001943A1 (es) 2018-03-02
PE20171241A1 (es) 2017-08-24
CO2017007662A2 (es) 2017-10-20
WO2016126552A1 (fr) 2016-08-11
EA201791516A1 (ru) 2018-01-31
CR20170352A (es) 2017-09-29
AU2016215643A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
EP3397963A4 (fr) Inhibition de mapk p38 pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
MA42999A (fr) Polythérapie pour le traitement de malignités
HUE059694T2 (hu) Készítmény rák kezelésére
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
EP3383547A4 (fr) Ensembles électromagnétiques pour le traitement de fluides
EP3400011A4 (fr) Combinaisons anti-cd20 pour le traitement des tumeurs
EP3359192A4 (fr) Polythérapie pour le traitement du cancer
MA41555A (fr) Polythérapie pour le traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3383497A4 (fr) Nouveaux anticorps pour le traitement de cancers
EP3383407A4 (fr) Conjugués de cytarabine pour le traitement du cancer
MA46963A (fr) Méthodes pour déterminer le dosage de céllules car-t
EP3331510A4 (fr) Thérapies combinatoires pour le traitement du cancer